Tabriz University of Medical Sciences Advanced Pharmaceutical Bulletin 2228-5881 14 3 2024 10 10 Nanomedicine Strategies Utilizing Lipid-Based Nanoparticles for Liver Cancer Therapy: Exploring Signaling Pathways and Therapeutic Modalities 513 523 10.34172/apb.2024.061 EN Fereshteh Asgharzadeh https://orcid.org/0000-0002-8349-3722 Maryam Moradi Binabaj Sahar Fanoudi William C. Cho Yu-jeong Yang Maryam Azarian Mehdi Shafiee Ardestani Nasim Nasiri Marzieh Ramezani Farani https://orcid.org/0000-0002-4184-5670 Yun Suk Huh https://orcid.org/0000-0003-1612-4473 REVIEW 10.34172/apb.2024.061 2024 05 14 2024 07 29 Liver cancer, specifically hepatocellular carcinoma (HCC), is the second leading cause of cancer-related deaths, following pancreatic cancer. The 5-year overall survival rate for HCC remains relatively low. Currently, there are multiple treatment options available for HCC, including systemic drugs, minimally invasive local therapies such as radiofrequency ablation, transarterial chemoembolization (TACE), and arterial radioembolization (TARE), as well as surgical interventions like liver resection or transplantation. However, the effectiveness of drug delivery to the cancerous liver is hindered by pathophysiological changes in the organ. In order to address this challenge, lipid-based nanoparticles (LNPs) have emerged as promising platforms for delivering a diverse range of therapeutic drugs. LNPs offer various structural configurations that enhance their physical stability and enable them to accommodate different types of cargo with varying mechanical properties and degrees of hydrophobicity. In this article, we provide a comprehensive review of the current applications of LNPs in the development of anti-HCC therapies. By examining the existing research, we aim to shed light on the potential future directions and advancements in this field.